4% P % 11.1%1, % %1, %1, % 3.5%1, % %1, % Santen Ph
|
|
|
- そうりん ふくだ
- 5 years ago
- Views:
Transcription
1 Financial Section Santen Pharmaceutical Co., Ltd. Annual Report
2 4% P % 11.1%1, % %1, %1, % 3.5%1, % %1, % Santen Pharmaceutical Co., Ltd. Annual Report 215
3 % %23 27 % , , ,59 9,629 6,868 6,76 2,569 2, , ,32 136,88 125,33 1,251 1,595 6,44 2,94 2, , (6.1) (12.6) (13.1) (7.4) 1.6 % 2, 4 1,618 1,463 1,18 1,144 1, , % % 17.4% % % %21.9% % Santen Pharmaceutical Co., Ltd. Annual Report
4 16.2% % %33.% 28.% % ,42 ROA 8.9%1, %49.5% % % 14.9%1 EPS EPS EPS 1 EPS ROA 3,5 1,988 1,996 1,848 1, ROA % 3 3,42 2, , %69.6% 1 13.% ROE11.1%12.% 52 Santen Pharmaceutical Co., Ltd. Annual Report 215
5 ROE 2,5 1,25 ROE % 3 2,118 1,872 1,561 1,645 1, ROE 13% 4% ROE 12.% ,386 26,686 (1,3) (61,79) (7,847) (53,862) 28,96 (7,954) 36,914 65,923 72,397 (6,474) Santen Pharmaceutical Co., Ltd. Annual Report
6 54 Santen Pharmaceutical Co., Ltd. Annual Report % PL % 54 Santen Pharmaceutical Co., Ltd. Annual Report % PL %
7 55 Santen Pharmaceutical Co., Ltd. Annual Report % PL 55 Santen Pharmaceutical Co., Ltd. Annual Report % PL
8 : 92,696 98,398 1,486 13,394 33,71 34,535 35,484 36, ,4 42,868 44,59 46,51 18,982 2,995 2,412 2,371 18,436 2,342 21,39 2,483 7,413 7,319 7,891 7,832 11,23 13,23 13,148 12,651 4,97 2,16 3,556 3,151 4,75 4,824 4,761 4,593 12,62 13,971 13,663 12, , , , , : 6,619 2,879 14,959 15,468 (2,97) (1,33) (5,846) (2,83) (12,712) (5,9) (5,691) (11,415) ,98 15, ,99 156,547 32,676 3,395 3,485 29,849 82,735 93,893 1,82 12,754 18,24 118, , ,998 6,882 5,614 5,446 5,278 ROE% ROA% % % PER DOE% ,659 86,751 86,825 86,867 2,38 2,312 2,49 2, Santen Pharmaceutical Co., Ltd. Annual Report 215
9 ,619 11,594 11, , ,66 146,26 161,831 $1,346,68 35,947 34,71 34,437 35,385 41,51 57,353 56, ,17 5,178 46,244 45,636 52,299 52,884 41,642 48,893 46,864 15,494 29,64 3,739 26,732 24,681 29,878 35, ,369 15,824 28,61 31,74 27,791 25,592 3,361 35, ,437 5,71 9,887 9,741 1,63 9,71 1,643 11,831 98,452 1,123 18,723 21,333 17,161 16,521 24,32 199,985 2,953 1,315 1,651 3,281 3,69 5,879 66,44 552,889 4,21 3,421 2,976 2,949 3,291 2,841 6,958 57,899 18,458 14,123 13,221 17,225 16,72 16,862 17, , $ , , , , , ,849 26,11 17,768 21,483 9,943 26,686 25,386 $ 211,248 (5,619) (829) (7,676) (1,273) (4,596) (7,847) (61,79) (513,514) (11,373) (6,753) (1,57) (8,559) (21,557) (7,954) 28,96 24, ,285. 3,37.8 2, ,12 166, ,81 198,81 199, ,64 34,2 $2,531,411 28,665 26,574 24,957 25,523 27,42 27,175 29,14 242,188 11,53 118, ,668 14, , ,241 15,672 1,253, , , ,99 164, ,88 187,21 211,779 1,762, ,351 21, ,916 86,992 87,53 87,147 82,469 82,583 82,653 2,69 2,756 2,867 3,53 3,5 3,72 3,23 Santen Pharmaceutical Co., Ltd. Annual Report
10 ,26 (57,353) 88,97 (41,642) (19) (16,862) 681 (1,16) 29, (433) 3,361 (1,643) 161,831 (56,373) 15,458 (48,893) (3,979) (17,477) 723 (458) 35, (279) 35,863 (11,831) 24,32 $1,346,68 (469,17) 877,573 (46,864) (33,111) (145,437) 6,19 (3,811) 294,369 6,392 (2,324) 298,437 (98,452) 199, , ,863 2,524 65,442 4,752 27, ,446 2,6 7,26 27,11 24,32 24,32 199, ,985 27,169 27,169 32,446 32,446 27,11 $ 27, $ Santen Pharmaceutical Co., Ltd. Annual Report 215
11 59 Santen Pharmaceutical Co., Ltd. Annual Report $ 242,188 72, ,964 24,784 19,39 1,277, , ,45 1,552 22,74 548,581 1,253,822 1,253,822 21,958 45,43 12,15 23,914 7,937 3, ,57 16,593 55,993 9,962 73, ,827 61,439 67,217 (158) 1,488, ,65 1,762,33 1,762, ,175 26,61 23,334 5,215 2,65 84, ,63 22,65 19,35 5,11 2,234 76,218 29,14 84,433 34,725 2,978 2, ,528 19,461 53,986 4,587 2,356 72, , ,241 2,35 45,324 2,217 2,45 6,237 13, ,542 2,133 61, ,728 65,923 15,672 15, ,64 26,76 34,2 2,531,411 5,43 38,93 92, ,64 26,76 34,2 769,81 $2,531, ,41 1,467 2,795 1,479 11, ,966 1,278 2,395 1,7 1,787 25,351 5,459 1,444 2, ,81 19,72 4,88 8, ,157 39,186 13,766 5,846 3, ,634 28,116 2,25 19,298 6,729 1,197 8,866 56,34 7,264 7, ,727 9, ,21 187,21 7,81 7,776 (2) 15,516 2, , ,857 7,383 8,77 (18) 178,84 17, , , Santen Pharmaceutical Co., Ltd. Annual Report $ 242,188 72, ,964 24,784 19,39 1,277, , ,45 1,552 22,74 548,581 1,253,822 1,253,822 21,958 45,43 12,15 23,914 7,937 3, ,57 16,593 55,993 9,962 73, ,827 61,439 67,217 (158) 1,488, ,65 1,762,33 1,762, ,175 26,61 23,334 5,215 2,65 84, ,63 22,65 19,35 5,11 2,234 76,218 29,14 84,433 34,725 2,978 2, ,528 19,461 53,986 4,587 2,356 72, , ,241 2,35 45,324 2,217 2,45 6,237 13, ,542 2,133 61, ,728 65,923 15,672 15, ,64 26,76 34,2 2,531,411 5,43 38,93 92, ,64 26,76 34,2 769,81 $2,531, ,41 1,467 2,795 1,479 11, ,966 1,278 2,395 1,7 1,787 25,351 5,459 1,444 2, ,81 19,72 4,88 8, ,157 39,186 13,766 5,846 3, ,634 28,116 2,25 19,298 6,729 1,197 8,866 56,34 7,264 7, ,727 9, ,21 187,21 7,81 7,776 (2) 15,516 2, , ,857 7,383 8,77 (18) 178,84 17, , ,
12 6 Santen Pharmaceutical Co., Ltd. Annual Report 215 7,81 7,776 (2) ,516 2,162 2,236 2, ,959 (7) (7) (8,25) 743 (7,57) 162,727 (463) (463) (28) (28) 4,118 4,752 4, , ,857 27, ,857 27,169 4,752 (49) (49) 124 (743) (668) 9, (7) (8,25) 124 (7,816) 187, (7) (8,25) 124 (7,816) 187, , Santen Pharmaceutical Co., Ltd. Annual Report 215 7,81 7,776 (2) ,516 2,162 2,236 2, ,959 (7) (7) (8,25) 743 (7,57) 162,727 (463) (463) (28) (28) 4,118 4,752 4, , ,857 27, ,857 27,169 4,752 (49) (49) 124 (743) (668) 9, (7) (8,25) 124 (7,816) 187, (7) (8,25) 124 (7,816) 187, ,
13 61 Santen Pharmaceutical Co., Ltd. Annual Report ,264 7, ,727 24,32 24, ,118 7,863 7, ,77 (18) (8,259) 34 (7,919) 178,84 (33) (33) (37) (37) 11, , , ,21 24,32 32, ,21 24,32 32,446 5, (32) (32) 186 (34) (186) 17,497 2 (8,259) 186 (7,877) 211, (8,259) 186 (7,877) 211, , Santen Pharmaceutical Co., Ltd. Annual Report ,264 7, ,727 24,32 24, ,118 7,863 7, ,77 (18) (8,259) 34 (7,919) 178,84 (33) (33) (37) (37) 11, , , ,21 24,32 32, ,21 24,32 32,446 5, (32) (32) 186 (34) (186) 17,497 2 (8,259) 186 (7,877) 211, (8,259) 186 (7,877) 211, ,
14 $6,449 $66,227 $(78) $1,354, , ,985 $ $34,264 2,524 65,442 2,524 65, (8) (68,732) $61, $67,217 (8) $(158) 2,833 (65,899) $1,488,227 (2,524) (2,524) $ (39) (39) $99, $39,548 2,6 2,6 $3,322 $ 77,134 7,26 7,26 $1,557, ,985 7,26 27,11 $1,557, ,985 7,26 27, $41,68 (267) 1,545 1,278 $4,6 (267) 1,545 (2,833) (1,555) $145,65 1,713 (8) (68,732) 1,545 (65,554) $1,762,33 1,713 (8) (68,732) 1,545 (65,554) $1,762,33 62 Santen Pharmaceutical Co., Ltd. Annual Report 215
15 63 Santen Pharmaceutical Co., Ltd. Annual Report $199,985 57,899 2,413 (4,46) 98,452 (64,88) (4,332) 1,48 6,336 21, ,925 (73) 1,53 (945) 34,53 (24,734) 5,455 (528,155) (492) (513,514) 673 4,562 (682) (117,23) 211, , (759) 1,643 (8,128) 1,411 5, ,883 33,413 24,32 6, (529) 11,831 (7,71) (521) 1, ,554 38,926 (111) 92 (4,825) 2,933 (3,461) 2 (2,418) (59) (7,847) (84) 184 (114) 4,149 (2,972) 656 (63,468) (6) (61,79) (7,34) 26, (82) (14,87) 25, ,254 (291,254) 332,862 (24,712) (68,769) 1,67 24,988 (61,278) 62,451 7,48 $548,581 (29) (8,247) 322 (7,954) 1,885 6,237 1,275 72,397 35, (35,) 4, (2,97) (8,264) ,96 (7,363) 72, , Santen Pharmaceutical Co., Ltd. Annual Report $199,985 57,899 2,413 (4,46) 98,452 (64,88) (4,332) 1,48 6,336 21, ,925 (73) 1,53 (945) 34,53 (24,734) 5,455 (528,155) (492) (513,514) 673 4,562 (682) (117,23) 211, , (759) 1,643 (8,128) 1,411 5, ,883 33,413 24,32 6, (529) 11,831 (7,71) (521) 1, ,554 38,926 (111) 92 (4,825) 2,933 (3,461) 2 (2,418) (59) (7,847) (84) 184 (114) 4,149 (2,972) 656 (63,468) (6) (61,79) (7,34) 26, (82) (14,87) 25, ,254 (291,254) 332,862 (24,712) (68,769) 1,67 24,988 (61,278) 62,451 7,48 $548,581 (29) (8,247) 322 (7,954) 1,885 6,237 1,275 72,397 35, (35,) 4, (2,97) (8,264) ,96 (7,363) 72, ,923
16 64 Santen Pharmaceutical Co., Ltd. Annual Report 215
C O N T E N T S 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 2009 Annual Report
C O N T E N T S 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 2009 Annual Report 1 1 2009 Annual Report 1. 2. 2 2 2009 Annual Report 3 3 2009 Annual Report 3. 1980 1991 1992 1993 1994
18年度石見美術館年報最終.indd
A Annual Report Annual Report B 1 Annual Report Annual Report 2 3 Annual Report Annual Report 4 Annual Report 5 Annual Report 6 7 Annual Report Annual Report 8 9 Annual Report Annual Report 10 11 Annual
untitled
financial report - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - -
ntv AR05 new/J
Financial Section 24 25 34 34 34 36 37 38 39 43 44 56 23 1999 2000 2001 2002 2003 2004 328,013 352,409 358,682 336,299 328,374 357,614 203,862 207,743 218,888 215,180 217,844 245,109 54,350 67,302 63,573
”‚’¶fi° JAR 97 Ł\”ƒ-1
1997 1996 1995 588,572 42,898 19,152 560,821 37,012 17,507 540,361 26,490 11,382 1997 5,118,017 373,026 166,539 436,705 94,610 57,257 404,181 101,675 54,965 387,314 97,606 55,441 3,797,435 822,695 497,887
80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54
2005 2005 3 Looking ahead 80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54 20052004 3 2005 3 2004 3 2005/2004 2005 3... 92,696 89,858 3.2% $ 863,175... 18,982
橡企業説明会.PDF
March 11 2004 CREDIT SAISON CO., LTD. CONTENTS. 1951 5 1 633 3,703 17,140 3 31 6,605 100 1,633 170-6073 12 166 1 3-1-1 60 52 03(3988 2111 2003 3 31 36 36 NILSON REPORT 656NOV.1997 706DEC.1999, 729DEC.2000&753DEC.2001&777DEC.2002
1 2003 7 2005 6 2 1 2000 2002 2003 80.052 86.7 39 26.374 3 3 2 2 8 500 8 2008 6.4 10.3% 10 2008 3 11.7 10.6 9.9 9.3 3 1998 100 1999 3 71.2 2005 2007 17.9 14.1 1989 4 20 6 4 2004 1 4 5 5 ROA ROE 5 6 60
アニュアルレポート 2017
2017 Financial Section 16 5 17 20 22 22 23 24 25 36 16 ISUZU MOTORS LIMITED 5 2017 2016 2015 2014 2013 2017 : 1,953,186 1,623,948 329,238 182,793 146,444 152,022 148,921 93,858 1,926,967 1,574,885 352,081
ROE
26 49 41 26 1,074 159 3 1,074 1,200 26 10 10 11 10 589 54.8% 159 26 10 10 11 10 86 54.1% 26... 1... 2... 2... 2... 3... 5... 6... 6... 7 ROE... 9... 10... 11... 11... 13... 14... 14... 15... 15... 16...
PowerPoint プレゼンテーション
200831012 200810-12 200810-12 200710-12 669 749 700 7.0 % 70 116 99 16.5 % 599 633 600 5.4 % 331 331 312 6.0 % 328 328 308 6.5 % 191 191 171 11.4 % EPS 322 322 283 13.6 % 5,928 5,928 6,048-2.0 % EPS
Ricoh Company, Ltd. 1
24 1 34 4 4/8 4,486 4,66 4,691 +31 +25 +4.6% +4.6% +4.6% 4,394 4,29 4,68-221 -326-7.4% -4.7% -2.1% 8,88 8,95 8,76-189 -12-1.4% -.% +1.2% 3,881 3,868 3,638-229 -242-6.2% 43.7% 43.2% 41.5% 772 78 577-22
UNI_AR04_J_Cover
Unicharm Corporation Annual Report 2004 1 2 8 10 12 13 14 16 17 39 40 41 Unicharm Annual Report 2004 1 2004 2003 2002 2004 240,110 223,169 206,707 $2,265,189 30,727 25,793 18,974 289,878 16,240 12,879
8% No
Our vision... 24 24 3 8% No.1 3... 4 23-25... 6... 6... 8... 12... 14... 15... 16... 24... 25... 26... 28... 29... 53... 54... 55 for growth Santen Annual Report 24 1 for the future 2 Santen Annual Report
P.7 56
Financial Section http://www.santen.co.jp/ja/ir/document/securities.jsp 55 P.7 56 57 57 58 59 60 60 61 2006 2007 2008 2009 98,398 100,486 103,394 101,619 34,535 35,484 36,513 35,947 28,897 30,926 33,569
6 1873 6 6 6 2
140 2012 12 12 140 140 140 140 140 1 6 1873 6 6 6 2 3 4 6 6 19 10 39 5 140 7 262 24 6 50 140 7 13 =1880 8 40 9 108 31 7 1904 20 140 30 10 39 =1906 3 =1914 11 6 12 20 1945.3.10 16 1941 71 13 B29 10 14 14
1 48
Section 2 1 48 Section 2 49 50 1 51 Section 2 1 52 Section 2 1 53 1 2 54 Section 2 3 55 1 4 56 Section 2 5 57 58 2 59 Section 2 60 2 61 Section 2 62 2 63 Section 2 3 64 Section 2 6.72 9.01 5.14 7.41 5.93
Section 1 Section 2 Section 3 Section 4 Section 1 Section 3 Section 2 4 5 Section 1 6 7 Section 1 8 9 10 Section 1 11 12 Section 2 13 Section 2 14 Section 2 15 Section 2 16 Section 2 Section 2 17 18 Section
6/9-98-資生堂-前半AR-6.5pm
1998 1998 3 1998 1997 1996 620,910 39,278 16,868 588,572 42,898 19,152 560,821 37,012 17,507 1998 4,776,231 302,139 129,754 457,333 99,310 64,267 436,705 94,610 57,257 404,181 101,675 54,965 3,517,946
ブック 1.indb
20 29 29 18 21 29 10 30 31 10 11 12 30 13 10 30 14 11 30 15 12 16 13 17 14 18 15 19 16 20 17 21 18 10 20 29 82 83 84 85 86 87 88 20 10 89 20 12 11 90 20 13 12 91 20 14 13 92 20 14 14 93 15 15 94 15 16
名称未設定-2
1 2 3 4 6 11 13 15 16 17 20 24 26 27 28 30 31 32 33 CONTENTS KENSHIN ANNUAL REPORT 2008 KENSHIN KENSHIN KENSHIN KENSHIN ANNUAL REPORT 2008 KENSHIN 19 KENSHIN ANNUAL REPORT 2008 KENSHIN ANNUAL REPORT 2008
* Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3
2010 for the Future Reaching Out 2010 2010 3 * Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3 3 31 2010 2009 2010/2009
21322* IR * 2 * 1 *1 *2 *3 IRIR *4 *5 *6 *7 *8 * 4 * 3 * 7 * 3 FATCA VBI VBI M&A M&A * 4 * 7 * 5 ALM * 9 * 8 * 8 * 6
213 25121 6 J. J.C. M. 3 22 VBI 211 1 J.C. 21322*9 25126 IR * 2 * 1 *1 *2 *3 IRIR *4 *5 *6 *7 *8 * 4 * 3 * 7 * 3 FATCA VBI VBI M&A M&A * 4 * 7 * 5 ALM * 9 * 8 * 8 * 6 2312 3 213 6 13 5 15 4 16 2 4 5 9
untitled
200710 1026 2 3 3 2007101 4 LAC LAC IT Little earth Corporation LAC LAC 5 LAC 6 7 SI 8 9 9 10 11 IT IT IT IT IT IT IT LAC LAC AI 12 13 CSR CSR 14 15 15 16 ; LAC 0612/A&I 073 17 720 18 19 20 % 203 220 255
STC-IP10
1 2 3 1 1 4 5 6 7 8 1 9 2 3 4 5 6 10 7 8 11 12 9 10 11 12 13 13 1 2 14 3 4 5 6 7 15 8 16 9 17 10 11 12 18 13 14 15 19 1 2 20 1 2 21 3 4 5 22 1 2 3 4 23 1 2 1 24 2 3 4 5 25 1 2 3 26 1 2 3 4 27 1 2 28 1
untitled
CONTENTS 1 2 4 6 8 10 11 12 14 15 16 17 18 19 20 21 22 23 24 27 28 29 30 31 32 33 Top Message 2 Daifuku Co., Ltd. CSR Report 2010 Daifuku Co., Ltd. CSR Report 2010 3 4 Daifuku Co., Ltd. CSR Report 2010
Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32 34 35
MANDOM Corporation Annual Review 2005 Construct the Foundation for Next Growth Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32
(6) (111) (148) (129) (169) CAPCOM ANNUAL REPORT
62 63 65 69 71 72 73 74 91 61 CAPCOM ANNUAL REPORT 213 22 26 276 143 92 13 113 73 122 (6) (111) (148) (129) (169) 23 24 25 27 28 29 21 211 212 213 CAPCOM ANNUAL REPORT 213 62 63 CAPCOM ANNUAL REPORT 213
会社説明資料
http://www.softcreate.co.jp/ Softcreate Co., Ltd. IT COMhttp://www.tokka.com/ 2-22-3 U R L http://www.softcreate.co.jp/ 44,4501,212,000 17417228 55,68,35,16 5 2 8 2 IT Web 3 5 13 ecbeing 12 15 X-point
2,347 232 01
27 194120331 JAPAN ASIA INVESTMENT CO., LTD. P01 P03 P05 P07 P08 P09 P10 P11 P13 P14 2,347 232 01 02 03 04 05 06 07 08 09 10 11 20,051 5,550 4,796 3,049 88,123 10,750 13,521 30,190 55,162 21,444 5,172
Annual Report UFJ 2 UFJ UFJ 1
2017 2 2017 11 14 Annual Report UFJ 2 UFJ UFJ 1 2017 2 MUFG B/S 2017 ( ) 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 2 2017 2 *1 1,364 9,500 65.9% 6,269 Tier1 *2 1 18 1,000 : 16 17 1 19,694 20,081 387 2 12,440
Eyeing the Next Stage
Eyeing the Next Stage 2014 3 2014 Our Values CONTENTS 1 2 6 8 10 18 24 26 30 36 38 42 47 48 49 89 90 92 At a Glance CEO CSR 2014 3 12 3 31 IMSJPM 2014 IMS Health IMS-JPM 2009.4-2014.3 1 1. 1890 120 Santen
KDDI Annual Report 2002
pg.22 KDDI CORPORATION Annual Report $ 515 3,610 (194) 734 247 275 5,187 21,239 3,607 975 483 1,081 141 27,526 (12,882) 14,644 489 298 1,833 460 378 842 (90) 4,210 $24,041 68,596 481,064 (25,793) 97,797
01(全頁)FinancialReport2012.pdf
Financial Report 2012 KYOTO UNIVERSITY 02 03 04 05 06 08 10 12 14 16 18 19 20 22 24 25 26 27 28 30 02 Kyoto University Financial Report 2012 MD&A Kyoto University Financial Report 2012 03 04 Kyoto University
2010年愛知教育大学年次報告書
Annual Report Aichi University of Education 875 (3)1764 (5)2357 (8)4121 4.71 (2)1332 (4)1602 (6)2934 3.35 462 (2)578 (2)1040 439 (2)548 (2)987 643 1239 (1)1443 (1)2682 4.17 950 (1)1024 (1)1974
2014度事業報告書p000_018.indd
2014 Junior Chamber International Japan Annual Report 2014 Junior Chamber International Japan 2014 Junior Chamber International Japan Annual Report 2014 Junior Chamber International Japan Annual Report
a s d a s 30 d a s d 1229 10 1221 a s d 16181717 a s d 21 a s a 16 s 105 21 1620312020 1620312015 10500 05775 03675 01050 E { F ROE ROE 1,472,479 6,118,098
untitled
ANNUAL REPORT 28 28 3 28 3 1. 1, 35.4% 2. 11.7% 8.1% 3. 17.9% 29.3% 4. Contents 2 4 6 1 12 14 7 1 16 1 18 2 28 3 2 21 22 23 & 24 CSR 26 28 29 57 58 59 Annual Report 28 1 2728 3 28 27 28 336,864 31,88 $
untitled
215 7 7 72 9 9 91 92 92 94 96 126 129 13 131 133 133 134 136 137 137 141 141 143 144 146 15 153 166 167 169 169 17 3 174 218 22 224 69 215 7 26 2733127 179912 191 ALM 1 1 1 1 26 397,394 73,82 67,873 81,368
c3 FAST RETAILING ANNUAL REPORT 2006
c3 FAST RETAILING ANNUAL REPORT 2006 FAST RETAILING ANNUAL REPORT 2006 c4 2 FAST RETAILING ANNUAL REPORT 2006 FAST RETAILING ANNUAL REPORT 2006 3 4 FAST RETAILING ANNUAL REPORT 2006 FAST RETAILING ANNUAL
,55 421, , , , , , , ,83 33, % 65.3% 63.% 63.4% 63.7%
TOTO 218 28 29.3 29 21.3 21 211.3 211 212.3 212 213.3 464,55 421,929 433,557 452,686 476,275 311,765 275,639 273,259 286,83 33,231 67.1% 65.3% 63.% 63.4% 63.7% 146,174 139,699 146,284 147,12 149,667 31.5%
Microsoft Word _urbanet_2016_06_q4_report_2016_09_16_japanese.doc
URL: www.walden.co.jp E-mail: yoshiyuki_muroya@walden.co.jp 03 (3553) 3769 3242 EPS DPS BPS FY06/2016 17,704 2,005 1,720 1,139 45.6 16.0 234.6 FY06/2017 18,000 2,300 1,900 1,270 50.9 18.0 - FY06/2016 48.6%
1QX
2008 Environment Report by Daiki Aluminium Industry Co., Ltd. 1 C O N T E N T S 1 3 5 6 7 8 9 11 12 13 17 19 21 22 2 G& 3 G & G Top Message Top Message G & G G4 5 6 7 8 9 T O P I C S 10 T O P I C S 11
010_9553901302406.indd
2011 WDB REPORT CONTENTS 1 WDB Holdings co.,ltd. Annual Report 2011 2 WDB Holdings co.,ltd. Annual Report 2011 3 WDB Holdings co.,ltd. Annual Report 2011 4 WDB Holdings co.,ltd. Annual Report 2011 5 WDB
BA-100_Ver3.05
JA Windows 1 2 3 4 5 6 7 8 10 1 1 2 11 1 2 3 12 1 1 1 13 1 2 3 1 2 3 14 4 1 5 6 7 2 3 15 16 17 18 19 20 21 22 1 2 3 23 24 25 26 1 2 3 1 2 27 1 2 3 1 28 2 3 4 1 2 1 2 3 4 29 5 6 1 2 3 1 2 3 4 1 2 3 30
7532_05arj.pdf
Don Quijote Evolving with Customers 25 25 P ROFILE 1989 1 24 DonQ 22 1725 6 C ONTENTS 2 4 7 14 33 35 Distinctive Advantages uijote 3 1,m 2 3 5m 2 24 3 1 U.S. 6 31 25 24 25 232,778 192,84 $2,14 1,814 1,611
;;; ;;; ;; ;; ;; ;; ;; ;; ;; ;; ;;;; ;;;; ;;;; ;;;;; ;;;; ;;;; ;;;; The World Bank Annual Report World Development
第11期 年次報告書
Top message 1961 1986 1986 2000 1 Nippon Commercial Development REPORT Nippon Commercial Development REPORT 2 Top message 20,000 15,492 15,000 11,201 10,000 7,993 1,200 1,200 1,000 1,000 800 800 600 600
untitled
27.4.1 s 28.3.31 31 8515 Vol.24 June 28 Top Message 283 1 16 4 17 5 Topics 18 CSR 7 19 1 2 12 21 21 4,574,99 321,63274 1 3 Top Message 2 4,112 33 317 2825 7 64%5% ROA1.5% 5, 1, 15, 2, 25, 3, 25,225 25/3
Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Sect
We Make It Happen 2012 2011412012 331 Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Section 39 49 51
Annual Report 2009
Creating New Value 1 3 5 7 9 11 25 25 28 31 33 35 76 77 79 80 43 54 55 56 75 43 45 48 51 53 1 3 9 11 13 37 37 38 39 40 41 17 P3~6P12Q2P25~36P43~49 P51~74 P14~15Q4Q5P17~24P27 P30P32P34P36 P16Q6Q7 P6P10P12Q1P18P25~36
Nippon COMSYS Corporation
22 Investors Guide 1 2 4 5 6 9 1 11 23 24 26 27 28 29 3 31 32 1 2 19/3 19/3 2/3 21/3 22/3 235,923 229,875 228,518 229,211 213,5 225,313 22,522 231,75 222,22 231,351 14,348 14,261 15,559 11,628 1,5 14,879
CONTENTS CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM
Eyeing Further 213 213 3 Specialization CONTENTS 1 2 4 6 12 18 2 24 3 32 36 4 41 77 78 8 CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM 28.4-213.3 1 1. 189 189 12 P.12 P.24 8.3% 2 1 No.2 39.7% 5.4% No.2 19.1%
DocuPrint C5450 ユーザーズガイド
1 2 3 4 5 6 7 8 1 10 1 11 1 12 1 13 1 14 1 15 1 16 17 1 1 18 1 19 1 20 1 21 1 22 1 23 1 24 1 25 1 26 27 1 1 28 1 29 1 30 1 31 1 2 12 13 3 2 10 11 4 9 8 7 6 5 34 24 23 14 15 22 21 20 16 19 18 17 2 35
【アニュアルレポート】
Unparalleled Innovation and Customer Satisfaction For Local Communities in Japan and Increasingly Overseas 2012 2012 3 457 BIZ-e- 6 AA Yamato Holdings Co., LTD. 2 4 5 12 14 16 16 18 BIZ- 20 22 e- 24 26
, , , , , , , , , , , , ,
4ROIC WACC ROICWACC 2 ROICWACC EVA* WACC3% EVA 2019 177 2019EVA EVA5,892 2,907 20186 8,800 2019 * EVA Stern Stewart & Co. WACC WACC ROIC ROIC WACC 367 2019 190 EVA 177 EVA177WACC5,892 5,8922,9078,800 8,8002019
STC-W10
STC-W10 2013 CASIO COMPUTER CO., LTD. 1 2 3 4 5 6 7 8 9 10 11 2.4 DS / OF4 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
1 2 3 4 5 6 7 a a a a a a 
c c c c c 1 c c c c c c c c c c c 2 3 c c 4 a a a a a a a a a 
もくじ１
Andplus Co. Ltd Andplus Co. Ltd Andplus Co. Ltd Andplus Co. Ltd Andplus Co. Ltd Andplus Co. Ltd Chapter1 インストール 方 法 chapter1 1-0 Andplus Co. Ltd. chapter1 1-1 Andplus Co. Ltd. chapter1 1-2 Andplus Co.
OLC 1961983 1km 21 2 4 2 OLCOLC 1 1 3 4 5 7 Innovate OLC 21 9 CSR 15 16 18 19 21 22 22 8 23 24 31 51 52 1 Oriental Land Annual Report Oriental Land An
3 INNOVATE OLC 21 www.olc.co.jp OLC 1961983 1km 21 2 4 2 OLCOLC 1 1 3 4 5 7 Innovate OLC 21 9 CSR 15 16 18 19 21 22 22 8 23 24 31 51 52 1 Oriental Land Annual Report Oriental Land Annual Report 2 19 2533
3号表し
Jichi Medical School Annual Report of Nursing 13 13 a 15 16 18 18 19 20 21 25 25 27 29 31 34 36 37 39 45 45 46 46 47 49 50 50 51 200416 55 55 56 2002 740 880 16201997 12 21 3 15 1516 1 10 3 513 1235000
大和ハウスグループ アニュアルレポート2009
CEO COO CFO 18 19 Dear Stakeholders Building a New Era with Heart 20 2008 4 2 3 Challenge 2010 2008 35.3% GDP 2008 1.1% 1 6,909 5 6 735 817.4% 398 5 535.0% 41 768.1% ROE 0.7%9.0% 1 24 22009 20207 9 1002055
平成22年12月期（第9期）決算説明資料
MID 9 22 7 1 22 12 31 MID http://www.midreit.jp/ 2 MID 3 70% 70% 21 OBP OBP IMP Value Up NOI MID MID MID MID MID MID MID 5 23 1 31 92.75 MID MID MID 100 MID 23 1 31 MID MID22 3 22400 22 3 22 9 22 4 22
STC-PC10_Ver1.01
JA Windows 1 3 4 5 6 1 8 1 8 1 2 1 3 5 6 2 4 7 1 9 2 3 4 5 Χ 7 8 1 6 2 3 4 5 10 1 2 3 4 5 6 11 12 2 1 2 1 13 3 4 1 2 14 2 1 2 1 15 3 4 16 1 2 17 3 1 18 2 19 2 1 20 3 4 21 5 1 6 2 7 3 8 4 22 2 1 23 3
fix_180824_小林製薬様_統合報告書2018_J_4C.indd
2017 Contents 01 03 04 06 08 10 12 20 23 26 30 31 34 35 36 38 40 11 46 MD&A 48 50 56 57 ESG IIRC 01 Something New / Something Different SimpleClearSpeed 02 2017 2017100 35 03 1886 1970 1975 1894 10 1994
CONTENTS
Annual Report 2017 CONTENTS Santen Pharmaceutical Co., Ltd. Annual Report 2017 1 Value Creation 2 Santen Pharmaceutical Co., Ltd. Annual Report 2017 Santen Pharmaceutical Co., Ltd. Annual Report 2017 3
【アニュアルレポート】セグメント別事業概況
e- 2014 3 DAN-TOTSU3 HOP e- 2013 10 e- 18 Yamato Holdings Co., ltd. 2014 2 6.9%1 986 93 14.4% 358 74 2015 3 20143DAN-TOTSU3 STEP 32015 3 3 2. IT 3. 1. BtoB 2015 3KPI 4,000 2014 3 24 4,000 76 ee AnnuAl
PowerPoint プレゼンテーション
1 2 20083 3 4 5 6 7 8 2008 10-12 2008 10-12 2007 10-12 669 749 700 7.0 % 70 116 99 16.5 % 599 633 600 5.4 % 331 331 312 6.0 % 328 328 308 6.5 % 191 191 171 11.4 % EPS 322 322 283 13.6 % 5,928 5,928 6,048-2.0
Fuji Xerox Co., Ltd. All rights reserved.
2011 Fuji Xerox Co., Ltd. All rights reserved. 2 2011 Fuji Xerox Co., Ltd. All rights reserved. 2011 Fuji Xerox Co., Ltd. All rights reserved. 2011 Fuji Xerox Co., Ltd. All rights reserved. 2011 Fuji Xerox
untitled
Report 214 21412 FEATURE-1 1 HORIBA FPD HORIBA Report 214 2 FEATURE-1 HORIBACSR HORIBA HORIBA 1945 195 1955 196 1965 197 1975 1945 1953 197 1974 1971 195 ph 1964 M EXA 19771978 3 1,53 172 198 1985 199
_JTEKT 2015 AR 日本語版H1.4
Top Message 1 Annual Report 215 1 2 3 4 5 Contents 7 8 8 9 1 1 Consolidated Financial Highlight 14, 12, 1, 9,554 1,526 1,675 12,61 13,559 14 12 1 124.24 8, 6, 8 6 59.39 68.4 4, 4 38.91 4.55 2, 2 22 23